Back HCV Populations Children & Adolescents

DDW 2014: Sustained Response to Interferon Is Durable in Children with Hepatitis C

Children with hepatitis C treated with interferon-based therapy continued to show undetectable HCV viral load up to 7 years after achieving sustained virological response in the PEDS-C trial, researchers reported at Digestive Disease Week this month in Chicago.


Read more:

FDA Approves Pegasys plus Ribavirin for Children with Chronic Hepatitis C

The U.S. Food and Drug Administration (FDA) has approved pegyalted interferon alfa-2a (brand name Pegasys) plus ribavirin (brand name Copegus) for previously untreated children and adolescents age 5-17 with chronic hepatitis C virus (HCV) infection. alt

Read more:

HCV Polymerase Inhibitor PSI-938 Gets Fast Track Status

The U.S. Food and Drug Administration (FDA) last week granted a "fast track" designation for PSI-938, an investigational nucleotide analog hepatitis C virus (HCV) polymerase inhibitor being developed by Pharmasset.alt

Read more: